Pharming Group N.V. ADS each representing 10 (PHAR) Peer Comparison
$11.78
$-0.17
(-1.42%)
As on 27-Aug-2026 16:00EDT
Market cap
$839 Mln
Revenue (TTM)
$366 Mln
P/E Ratio
84.6
P/B Ratio
3.1
Div. Yield
0 %
Edit
| Pharming Group N.V. ADS each representing 10 (PHAR) | Zai Lab - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | Valneva SE - ADR | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
839 | 2,920 | 2,195 | 914 | 660 |
Revenue ($ Mln) |
366 | 450 | 549 | -- | 144 |
Net Profit ($ Mln) |
9.27 | -188.21 | 17.88 | -175.85 | -158.17 |
Net Margin (%) |
2.53 | -41.86 | 3.26 | -- | -110.21 |
RoE (%) |
3.39 | -28.46 | 1.43 | -106.84 | -168.93 |
Price to Earnings |
84.64 | -- | 126.30 | -- | -- |
Price-To-Book |
3.06 | 4.82 | 1.73 | 5.59 | 6.89 |
Income Statement ($ Mln)
| Pharming Group N.V. ADS each representing 10 (PHAR) | Zai Lab - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | Valneva SE - ADR | |
|---|---|---|---|---|---|
|
Operating Revenue
|
366.45 | 449.61 | 549.12 | 0.00 | 143.51 |
|
Cost of Revenue
|
49.36 | 195.71 | 548.01 | 12.78 | 120.05 |
|
Gross Profit
|
330.63 | 269.08 | 212.72 | -17.67 | 67.52 |
|
Operating Expenses
|
304.74 | 517.90 | 35.89 | 176.86 | 139.61 |
|
Operating Profit (EBIT)
|
12.35 | -264.00 | -34.78 | -181.14 | -116.14 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
15.84 | -190.72 | 20.08 | -178.93 | -158.10 |
|
Provision for Tax
|
6.57 | -2.51 | 1.66 | -3.09 | 0.07 |
|
Profit after Tax (Net Income)
|
9.27 | -188.21 | 17.88 | -175.85 | -158.17 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Pharming Group N.V. ADS each representing 10 (PHAR) | Zai Lab - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | Valneva SE - ADR | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
270.49 | 607.04 | 1,260.78 | 160.40 | 81.09 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
104.25 | 39.17 | 186.25 | 8.50 | 203.74 |
|
Current Liabilities
|
93.25 | 428.58 | 275.21 | 54.30 | 103.29 |
|
Total Liabilities
|
499.81 | 1,172.38 | 1,753.10 | 233.72 | 398.84 |
Assets ($ Mln)
| Pharming Group N.V. ADS each representing 10 (PHAR) | Zai Lab - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | Valneva SE - ADR | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
187.30 | 160.76 | 183.02 | 21.30 | 165.33 |
|
Current Assets
|
280.69 | 914.04 | 1,553.41 | 201.90 | 222.79 |
|
Total Assets
|
499.81 | 1,172.38 | 1,753.10 | 233.72 | 398.84 |
|
Total Debt*
|
113.30 | 254.58 | 94.51 | 21.00 | 210.14 |
|
Net Current Assets
|
187.44 | 485.45 | 0.00 | 147.60 | 0.00 |
Cashflow ($ Mln)
| Pharming Group N.V. ADS each representing 10 (PHAR) | Zai Lab - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | Valneva SE - ADR | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
54.71 | -150.79 | -64.66 | -121.18 | -52.89 |
|
Cash Flow from Investing Activities
|
26.25 | 307.87 | -29.41 | -1.37 | -1.71 |
|
Cash from Financing Activities
|
1.50 | 72.35 | 7.84 | 276.18 | -0.62 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Pharming Group N.V. ADS each representing 10 (PHAR) | Zai Lab - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | Valneva SE - ADR | |
|---|---|---|---|---|---|
|
ROCE (%)
|
0.77 | -18.15 | 41.92 | -130.25 | -32.40 |
|
ROE (%)
|
3.39 | -28.46 | 1.43 | -106.84 | -168.93 |
|
ROA (%)
|
1.69 | -12.55 | 0.66 | -74.77 | -26.16 |
|
EBIT Margin (%)
|
8.34 | -41.09 | -6.33 | -- | -80.22 |
|
Net Margin (%)
|
2.53 | -41.86 | 3.26 | -- | -110.21 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | -- | -- | -- |
Growth Ratios
| Pharming Group N.V. ADS each representing 10 (PHAR) | Zai Lab - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | Valneva SE - ADR | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-99.61 | 5.10 | -8.81 | -1.00 | -26.90 |
|
EBIT Growth (%)
|
523.06 | 11.36 | -76.55 | -45.21 | -193.21 |
|
Net Profit Growth (%)
|
-99.68 | 11.44 | -96.17 | -43.04 | -135.93 |
|
EPS Growth (%)
|
-96.78 | -1.87 | -96.17 | 7.30 | -93.94 |
|
Book Value Growth (%)
|
7.71 | -25.05 | 2.54 | 108.85 | -64.71 |
Valuation Ratios
| Pharming Group N.V. ADS each representing 10 (PHAR) | Zai Lab - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | Valneva SE - ADR | |
|---|---|---|---|---|---|
|
Price / Earnings
|
469.58 | -11.11 | 5.08 | -9.99 | -6.64 |
|
Price / Book Value
|
4.83 | 2.73 | 1.88 | 8.70 | 7.20 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
36.65 | -9.39 | -25.58 | -9.30 | -17.09 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Pharming Group N.V. ADS each representing 10 (PHAR) | Zai Lab - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | Valneva SE - ADR | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.34 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
0.03 | 0.40 | 0.02 | 0.09 | 0.26 |
|
Current Ratio
|
3.01 | 2.13 | 5.64 | 3.72 | 2.16 |
|
Quick Ratio
|
2.31 | 1.92 | 5.50 | 3.72 | 1.69 |
|
Interest Coverage
|
2.08 | -30.87 | -19.05 | -- | -2.89 |
Operating Efficiency Ratios
| Pharming Group N.V. ADS each representing 10 (PHAR) | Zai Lab - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | Valneva SE - ADR | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
15.55 | 16.23 | 21.41 | -- | 11.38 |
|
Asset Turnover
|
0.67 | 0.30 | 0.20 | 0.00 | 0.24 |
|
Receivable days
|
51.78 | 77.60 | 104.79 | -- | 65.89 |
|
Inventory Days
|
492.02 | 109.55 | 49.57 | -- | 177.10 |
|
Payable days
|
466.91 | 231.78 | 47.68 | 650.68 | 37.01 |
|
Cash Conversion Cycle
|
76.89 | -44.63 | 106.67 | -- | 205.98 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
